I realize that it will be up to each individual to decide what’s right for herself, and I completely respect that. If it feels right, go for it.
We will probably never know whether the agency made a purely scientific judgment or whether a campaign called “Even the Score” unduly influenced it. This campaign was partly financed by the manufacturer and organized with the help of one of its consultants. It depicted the agency as gender-biased for never having approved a drug to treat sexual dysfunction in women while approving numerous drugs for men. There is no similarity between this drug and Viagra®. Viagra fixes a physical issue; lack of blood flow to male sex organs.
A man takes it, and presto, he’s ready to rock and roll when he and his sweetie climb out of their bathtubs at sunset. The pink pill, flibanserin, or Addyi® (the brand name), was first developed in the 1990s for depression but failed to show significant benefit. It increases levels sex power tablet of dopamine and noradrenalin and reduces levels of serotonin. How this translates into increased sexual desire isn’t clear. FDA rejected the drug twice, in 2010 and 2013, because of safety and effectiveness concerns.
Still, after women told an advisory panel in June how low libido had ruined their lives, the panel recommended approval for premenopausal women. Earlier this month, the agency followed that advice. In clinical trials, the drug showed VERY modest benefits. In one trial, women who took the pill had an average of 4.4 “satisfying sexual experiences a month” compared with 3.7 for women given a placebo. I’m not sure 7/10ths of a “satisfying experience” is worth it for a drug that requires daily use and has the potential for side effects such as drowsiness, insomnia, nausea, extremely low blood pressure, and loss of consciousness. I do have concerns, though, that women will feel pressured by their partners to try it or that they’ll feel like they now need to live up to some numerical standard that doesn’t match their natural desire. And as a health care provider, I worry that prescribers may not take the time to have an in-depth discussion about the dangers of mixing flibanserin with alcohol. In my mind, the best solution to a lack of sexual desire involves non-drug approaches, like therapy and mind-body techniques. We need to get our partners on board and engaged in the solution and address the root causes. There is no “mojo miracle” quick fix.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 200mg | 20 Pills | 61.69€ 58.75€ | |
| Levitra Generic | 20mg | 360 + 10 Pills | 458.44€ 436.61€ | |
| Kamagra Polo | 100mg | 120 + 6 Pills | 327.15€ 311.57€ | |
| Cialis Original | 20mg | 76 + 4 Pills | 319.19€ 303.99€ | |
| Cialis Super Active | 20mg | 270 + 30 Pills | 661.49€ 629.99€ | |
| Viagra Generic | 100mg | 20 Pills | 45.58€ 43.41€ | |
| Kamagra Gold | 100 mg | 20 Pills | 86.09€ 81.99€ | |
| Viagra Soft Tabs | 100mg | 60 + 6 Pills | 152.94€ 145.66€ | |
| Cialis Original | 20mg | 4 Pills | 41.99€ 39.99€ | |
| Cialis Black | 80mg | 180 + 10 Pills | 356.64€ 339.66€ | |
| Levitra Generic | 20mg | 10 Pills | 31.49€ 29.99€ | |
| Kamagra Gold | 100 mg | 120 + 6 Pills | 330.74€ 314.99€ | |
| Tadalista Super Active | 20mg | 270 + 30 Pills | 661.49€ 629.99€ | |
| Cialis Black | 80mg | 10 Pills | 43.27€ 41.21€ | |
| Viagra Generic | 50mg | 10 Pills | 26.87€ 25.59€ | |
| Cialis Generic | 2.5mg | 360 + 10 Pills | 260.03€ 247.65€ |
The use of mind-altering drugs to increase libido simply continues society’s pathologizing of normal behavior in women. The FDA’s approval of flibanserin creates a potentially dangerous situation and does women a disservice in the long run. Dr. Anna Garrett is a pharmacist and menopause expert who helps women who are struggling with symptoms of perimenopause and menopause find natural hormone balancing solutions so they can rock their mojo through midlife and beyond.
The original version of this story mischaracterized how the drug was approved for post-menopausal women. The FDA required an additional review of data Sprout had already provided; new studies were not conducted. The new documentary, The Pink Pill: Sex, Drugs and Who Has Control, looks at the decade-long fight to bring a pill for women's sexual health to market Addyi is a pill that can improve a woman’s libido, but concerns that women would “not make good choices” on it delayed its approval The documentary explores systemic gender inequalities that work against women's sexual health It’s a small pink pill that can help women regain control of their sexual health. That’s the question explored in the new documentary, The Pink Pill: Sex, Drugs and Who Has Control. The documentary — helmed by acclaimed director Aisling Chin-Yee (No Ordinary Man, Rest of Us, Plan B) — explores the inherent gender bias in women's health through stories of real women who restored their libido by using a little pink pill, Addyi.
Addyi is an FDA-approved, non-hormonal prescription medication that’s been mistakenly called “female Viagra.” But unlike that little blue pill, Addyi works in the brain, not the body — and instead of taking it before sexual activity, it’s meant to be taken daily to increase sexual desire in perimenopausal and menopausal women. “I feel like a new woman on this drug,” one woman who took the pill shares in the documentary’s trailer. But the road to approval wasn’t easy. It took entrepreneur Cindy Eckert, founder of Sprout Pharmaceuticals, which manufactures the drug, 10 years to get the green light. It was rejected by the Food and Drug Administration twice — and when it was approved, it had a black box warning, which has since been removed.
The film examines the systemic bias against women’s care, including concerns that women would “not make good choices” on the medication. There haven’t been, at least publicly, similar concerns about medications for male erectile dysfunction. “How do you take on the government for women's sexual pleasure?” Eckert says in the trailer. “You lean right into it and say, ‘This is the conversation we're going to have.'” The Pink Pill: Sex, Drugs and Who Has Control is now streaming through DOCNYC. The Food and Drug Administration’s recent approval of a marginally effective drug to enhance the sexual drive of women with low libido raises a lot of questions. But her clients would tell you that her real gift is helping them reclaim pieces of themselves they thought were gone forever. Dr.
It’s deeply affected by everyday life stress and relationships. There’s no pill on earth that can fix these things if they’re out of balance. Maybe a study should compare women who juggle all the day-to-day responsibilities of life with those who have a cleaning service, personal chef, and nanny. I’ll bet the ladies with the support team would be in the mood a lot more than those without. Low testosterone, body image, and self-esteem issues can also compound the problem. Anna offers a complimentary 30-minute Get Acquainted Call to anyone who’d like to learn more about working 1-1 with her.
You can schedule that at your convenience by clicking here. Please contact her at dranna@drannagarrett.com.
| Age Range | Percentage of Users | Main Reasons for Use | Average Duration of Use |
|---|---|---|---|
| 25-35 years | 40% | Mood improvement, libido boost | 3-6 months |
| 36-45 years | 35% | Menopause symptoms, energy enhancement | 6-12 months |
| 46-50 years | 25% | Hormonal support, sleep aid | Varies |
| All ages | N/A | General wellness | Ongoing |
EXPOSING GENDER BIAS IN HEALTH CARE, THE PINK PILL: SEX, DRUGS & WHO HAS CONTROL, PREMIERES AT DOC NYC ON 11/15/25. Toronto, ON/Washington, D.C. – October 9, 2025 – Producers Julie Britow of Catalyst and Abby Greensfelder of Everywoman Studios are proud to share THE PINK PILL: SEX, DRUGS & WHO HAS CONTROL, the boundary-pushing and essential documentary by award-winning director Aisling Chin-Yee (No Ordinary Man, The Rest of Us, Plan B) is confirmed to have its world premiere at DOC NYC on Saturday, November 15.
To me, the basis of that is that we believe women are entirely psychological creatures rooted in emotion, while men are biological creatures. That gives us as a society extraordinary permission to dismiss what women are experiencing, because once we decide that women are emotional, any symptom women report, they’re patted on the shoulder and told to relax. We’ve created a culture of dismissal. To me, this is a litmus test for what this conversation is going to be like. Now we are saying half of the population goes through this thing called menopause.
Now we are taking it, I hope, a little more seriously. It will be fascinating if this conversation is fundamentally different this time around. Addyi is a case study for whether things have actually changed. Pink is a bit of active defiance to me. When people were patting me on the shoulder, saying, ‘Oh the little pink pill,’ I recognized that in that was dismissiveness and trivialization, and that was the very conversation I wanted to have: you perceive [women’s loss of sexual desire] as weakness or unimportant, but I see it very differently.
I was criticized for wearing pink and was told people wouldn’t take me seriously. But I believe you always get two choices. You either lean back away from it and distance yourself, or you lean right in toward it. I always loved pink, and never saw it as a sign of weakness. I see it as a strength to show up exactly as you are. Sphere Abacus, which handles global sales, will also present the film to buyers at MIPCOM next week. Paramount+ is set to release the film in Canada in early 2026.
That list will get you out of the mood very quickly. The risks increase when patients drink alcohol or take certain medicines that interfere with the breakdown of flibanserin in the body such as Biaxin®, Ketek®, Cardizem®, and Diflucan®. Grapefruit juice can also have this effect. Doctors and pharmacists who will prescribe or dispense the drug must watch an online tutorial, pass a test demonstrating their comprehension, and counsel patients following FDA guidelines. In addition, the manufacturer will have to conduct three well-designed post-marketing studies to understand the interaction with alcohol better.
The FDA approved Flibanserin to treat HSDD (hypoactive sexual desire disorder) or female sexual interest/arousal disorder, which the DSM-V manual list as a mental disorder. This drug approval supports the notion that women who don’t seek sexual arousal are in some way broken and need to fix themselves. Who decides the number of sexual encounters a woman should desire? And if she desires less than the “average,” does she require a diagnosis and chemical manipulation of her brain? Attempting to treat lack of sexual desire with a “pink pill” ignores the fact that a woman’s desire for sex is COMPLICATED. THE PINK PILL: SEX, DRUGS & WHO HAS CONTROL explores the fight to put women’s sexual health on equal footing in a medical system that has long overlooked their needs.
At the center is entrepreneur Cindy Eckert, whose trademark pink and fearless determination made her a lightning rod in the battle to bring Addyi— which the media dubbed “female Viagra”—to market. Eckert confronted gender bias at the FDA head-on, ultimately winning approval in 2015 on the strength of science. Her victory, followed by a billion-dollar sale of Addyi, laid bare a double standard: while Viagra and more than twenty drugs for men were greenlit with ease, Eckert endured a decade of roadblocks, restrictions, and public attacks.